[{"id":"c2b67cc7-ce2b-4a17-af77-efced8e1526f","acronym":"E1609","url":"https://clinicaltrials.gov/study/NCT01274338","created_at":"2023-04-12T19:03:03.311Z","updated_at":"2025-02-25T16:36:09.391Z","phase":"Phase 3","brief_title":"Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery","source_id_and_acronym":"NCT01274338 - E1609","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IFNA1","pipe":"","alterations":" ","tags":["IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • Intron A (interferon α-2b)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1673","initiation":"Initiation: 05/25/2011","start_date":" 05/25/2011","primary_txt":" Primary completion: 02/15/2019","primary_completion_date":" 02/15/2019","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2025-02-06"},{"id":"a5a40164-7b7d-4529-a423-d8ca1d3b24fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT06582017","created_at":"2025-02-27T08:18:33.647Z","updated_at":"2025-02-27T08:18:33.647Z","phase":"Phase 1","brief_title":"Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma","source_id_and_acronym":"NCT06582017","lead_sponsor":"Nammi Therapeutics Inc","biomarkers":" IL6 • TNFA • IL2","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL2"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 08/28/2024","start_date":" 08/28/2024","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 05/30/2028","study_completion_date":" 05/30/2028","last_update_posted":"2024-09-02"},{"id":"af5b2b8c-e254-4a25-b607-944acb5d90e8","acronym":"SWOG S1404","url":"https://clinicaltrials.gov/study/NCT02506153","created_at":"2021-01-18T12:05:51.420Z","updated_at":"2024-07-02T16:35:01.870Z","phase":"Phase 3","brief_title":"Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery","source_id_and_acronym":"NCT02506153 - SWOG S1404","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • Intron A (interferon α-2b) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1345","initiation":"Initiation: 11/10/2015","start_date":" 11/10/2015","primary_txt":" Primary completion: 09/15/2023","primary_completion_date":" 09/15/2023","study_txt":" Completion: 01/23/2025","study_completion_date":" 01/23/2025","last_update_posted":"2024-05-22"},{"id":"ad6effdc-77e6-48b7-93c9-786714c4d278","acronym":"EXCEED ET","url":"https://clinicaltrials.gov/study/NCT05482971","created_at":"2023-07-03T18:10:07.965Z","updated_at":"2024-07-02T16:35:34.897Z","phase":"Phase 2","brief_title":"A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET","source_id_and_acronym":"NCT05482971 - EXCEED ET","lead_sponsor":"PharmaEssentia","biomarkers":" JAK2","pipe":" | ","alterations":" JAK2 mutation","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Besremi (ropeginterferon alfa-2b-njft)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 09/29/2022","start_date":" 09/29/2022","primary_txt":" Primary completion: 07/29/2024","primary_completion_date":" 07/29/2024","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-10-03"},{"id":"59bdfa97-7b2e-46bf-97c1-23ab33821d5c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04081389","created_at":"2021-01-18T19:59:01.001Z","updated_at":"2024-07-02T16:35:37.452Z","phase":"Phase 1","brief_title":"Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer","source_id_and_acronym":"NCT04081389","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" PGR","pipe":" | ","alterations":" ER positive + PGR positive • PGR positive","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive + PGR positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • doxorubicin hydrochloride • cyclophosphamide • daunorubicin • Intron A (interferon α-2b) • Ampligen (rintatolimod) • celecoxib oral • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 12/06/2019","start_date":" 12/06/2019","primary_txt":" Primary completion: 05/24/2022","primary_completion_date":" 05/24/2022","study_txt":" Completion: 02/27/2023","study_completion_date":" 02/27/2023","last_update_posted":"2023-09-11"},{"id":"23e94fe6-5db5-4814-8780-12a2c9a9dde5","acronym":"ENDURE-CML-IX","url":"https://clinicaltrials.gov/study/NCT03117816","created_at":"2021-04-28T11:52:33.963Z","updated_at":"2024-07-02T16:35:51.664Z","phase":"Phase 3","brief_title":"ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission","source_id_and_acronym":"NCT03117816 - ENDURE-CML-IX","lead_sponsor":"Philipps University Marburg Medical Center","biomarkers":" ABL1 • BCR • PD-1 • IL6 • IL10 • CD86","pipe":"","alterations":" ","tags":["ABL1 • BCR • PD-1 • IL6 • IL10 • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Besremi (ropeginterferon alfa-2b-njft)"],"overall_status":"Completed","enrollment":" Enrollment 214","initiation":"Initiation: 05/04/2017","start_date":" 05/04/2017","primary_txt":" Primary completion: 01/26/2022","primary_completion_date":" 01/26/2022","study_txt":" Completion: 12/12/2022","study_completion_date":" 12/12/2022","last_update_posted":"2023-03-31"},{"id":"2ef799d3-1ede-4380-b63e-812810bb7c1f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03403634","created_at":"2021-01-18T16:47:42.513Z","updated_at":"2024-07-02T16:36:16.175Z","phase":"Phase 2a","brief_title":"Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver","source_id_and_acronym":"NCT03403634","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" PD-L1 • MSI • CD8","pipe":" | ","alterations":" MSI-H/dMMR • RAS wild-type","tags":["PD-L1 • MSI • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Intron A (interferon α-2b) • Ampligen (rintatolimod) • celecoxib oral"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 04/19/2018","start_date":" 04/19/2018","primary_txt":" Primary completion: 12/23/2020","primary_completion_date":" 12/23/2020","study_txt":" Completion: 08/29/2021","study_completion_date":" 08/29/2021","last_update_posted":"2022-03-02"},{"id":"ea14f1dd-83ae-4642-802b-7e2c102f2e24","acronym":"","url":"https://clinicaltrials.gov/study/NCT00001114","created_at":"2021-01-17T22:44:07.416Z","updated_at":"2025-02-25T14:22:45.692Z","phase":"Phase 2","brief_title":"The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma","source_id_and_acronym":"NCT00001114","lead_sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","biomarkers":" CD4 • IFNA1","pipe":"","alterations":" ","tags":["CD4 • IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Intron A (interferon α-2b)"],"overall_status":"Completed","enrollment":" Enrollment 90","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":" Completion: 03/01/2000","study_completion_date":" 03/01/2000","last_update_posted":"2021-11-01"},{"id":"d160bba2-646c-4438-b590-5eb0c74d7442","acronym":"","url":"https://clinicaltrials.gov/study/NCT02151448","created_at":"2021-01-18T09:59:55.040Z","updated_at":"2024-07-02T16:36:43.024Z","phase":"Phase 1/2","brief_title":"αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies","source_id_and_acronym":"NCT02151448","lead_sponsor":"David Bartlett","biomarkers":" IL6 • TNFA • CXCL8 • CXCL10 • CXCL12 • IL10 • CXCL11","pipe":" | ","alterations":" IL10 elevation","tags":["IL6 • TNFA • CXCL8 • CXCL10 • CXCL12 • IL10 • CXCL11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL10 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Intron A (interferon α-2b) • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 07/01/2014","start_date":" 07/01/2014","primary_txt":" Primary completion: 02/18/2019","primary_completion_date":" 02/18/2019","study_txt":" Completion: 02/18/2019","study_completion_date":" 02/18/2019","last_update_posted":"2020-07-20"},{"id":"3e538d16-0aec-4c1f-b4d7-a136a14f96af","acronym":"","url":"https://clinicaltrials.gov/study/NCT01603212","created_at":"2021-01-18T06:51:25.271Z","updated_at":"2024-07-02T16:36:59.411Z","phase":"Phase 1","brief_title":"Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor","source_id_and_acronym":"NCT01603212","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IL2","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Intron A (interferon α-2b) • Proleukin (aldesleukin)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 07/18/2013","start_date":" 07/18/2013","primary_txt":" Primary completion: 07/05/2017","primary_completion_date":" 07/05/2017","study_txt":" Completion: 07/05/2017","study_completion_date":" 07/05/2017","last_update_posted":"2019-05-21"},{"id":"b2a99631-d050-4b24-a01c-610e13438bd0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01933906","created_at":"2022-04-24T08:56:26.993Z","updated_at":"2024-07-02T16:37:04.233Z","phase":"Phase 1","brief_title":"Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response","source_id_and_acronym":"NCT01933906","lead_sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • Besremi (ropeginterferon alfa-2b-njft)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 08/30/2013","start_date":" 08/30/2013","primary_txt":" Primary completion: 11/14/2018","primary_completion_date":" 11/14/2018","study_txt":" Completion: 11/14/2018","study_completion_date":" 11/14/2018","last_update_posted":"2019-01-04"},{"id":"3352753e-aefb-46b9-a859-11eaadd3d587","acronym":"","url":"https://clinicaltrials.gov/study/NCT01460875","created_at":"2021-01-18T06:04:28.765Z","updated_at":"2025-02-25T16:01:59.871Z","phase":"","brief_title":"Recombinant Interferon Alfa-2b in Treating Patients With Melanoma","source_id_and_acronym":"NCT01460875","lead_sponsor":"William Carson","biomarkers":" CD69 • IFNA1","pipe":"","alterations":" ","tags":["CD69 • IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Intron A (interferon α-2b)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 04/22/2008","start_date":" 04/22/2008","primary_txt":" Primary completion: 01/05/2014","primary_completion_date":" 01/05/2014","study_txt":" Completion: 01/05/2014","study_completion_date":" 01/05/2014","last_update_posted":"2018-11-02"},{"id":"69f33d3c-e7f9-433f-be3a-0180a4c484ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT01622933","created_at":"2021-06-22T23:52:48.057Z","updated_at":"2024-07-02T16:37:18.262Z","phase":"Phase 1","brief_title":"Multiple Antigen-Engineered DC Vaccine for Melanoma","source_id_and_acronym":"NCT01622933","lead_sponsor":"Lisa H. Butterfield, Ph.D.","biomarkers":" IFNA1","pipe":"","alterations":" ","tags":["IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Intron A (interferon α-2b)"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 06/01/2012","start_date":" 06/01/2012","primary_txt":" Primary completion: 05/01/2016","primary_completion_date":" 05/01/2016","study_txt":" Completion: 08/01/2017","study_completion_date":" 08/01/2017","last_update_posted":"2017-08-31"}]